Skip to content
Boost Up Blog – Lifestyle
Author:
Novastra Therapeutics Inc.
Novastra Therapeutics to Present First-in-Human Data for OAP-101 in Checkpoint-Refractory Advanced Melanoma at SITC 2026 Annual Meeting
October 29, 2026
Novastra Therapeutics Reports Encouraging First Clinical Data for Its Novel XIRT™/OAP Cancer Immune Therapy at ESMO Congress 2026
October 26, 2026
Novastra Therapeutics to Present Initial Phase 1 Data for OAP-101 in Anti–PD-1–Refractory Advanced Melanoma at ESMO Congress 2026
October 13, 2026
Novastra Therapeutics Appoints Chief Financial Officer as Company Advances Lead Candidate Toward Global Clinical Development
May 21, 2026